title: Pre-treatment predictors of response for assessing outcomes to standard treatment in infection with HCV genotype 3.
abstract: OBJECTIVE
  To determine the role of pre-treatment predictors of response in assessing outcomes to standard treatment in HCV genotype 3.
  
  
  METHODS
  Observational study.
  
  
  METHODS
  Department of Medicine, KRL General Hospital, Islamabad, from December 2004 to December 2006.
  
  
  METHODS
  All patients with positive anti-HCV and PCR genotype 3a were recruited and written and informed consent was taken. Patients were treated with standard Interferon plus Ribavirin therapy (IFN alpha-2a, 3MU t.i.w 24 weeks plus Ribavirin 1000-1200 mg/day) for 6 months. The effect of pre-treatment factors influencing outcome i.e. age, gender, weight, baseline ALT, necroinflammatory grade, fibrosis and steatosis on the final outcome were further analyzed by univariate logistic regression analysis.
  
  
  RESULTS
  Response rates to standard Interferon plus Ribazole therapy were studied in 190 patients. The end-of-treatment complete response (EOTCR) was seen in 81% (n=155) of the patients, whereas 17% (n=33) were non-responders (NR). Sustained viral response (SVR) was seen in 58% (n=112) patients and 24% (n=45) were relapsers. SVR was higher in patients without steatosis (OR=2.52, 95% CI=1.356- 4.71, p=0.04). Higher SVR was seen in patients weighing less than 65 kg, as compared with weight>65 kg (OR=2.277, 95% CI=1.246-4.161, p=0.007). The other variables were not found to be significantly associated with improved SVRs.
  
  
  CONCLUSIONS
  Out of the studied predictors, body weight and presence of steatosis, were statistically related to treatment outcome. Pre-treatment host factors can predict response to treatment that can help in individualizing treatment and patient selection and optimize treatment outcomes.
authors.affiliation: Department of Medicine, Khan Research Labs General Hospital, Islamabad. msqcdc@gmail.com
authors.forename: Saleem
authors.initials: S
authors.lastname: Qureshi
authors.forename: Uzma
authors.initials: U
authors.lastname: Batool
authors.forename: Mussarat
authors.initials: M
authors.lastname: Iqbal
authors.forename: Umar Farooq
authors.initials: UF
authors.lastname: Burki
authors.forename: Naqeeb Ullah
authors.initials: NU
authors.lastname: Khan
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D001706:Biopsy; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D016015:Logistic Models; D008297:Male; D016133:Polymerase Chain Reaction; D011237:Predictive Value of Tests; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin